NASDAQ: GNFTGenfit Sa Stock
$5.92+0.73 (+14.07%)
Updated May 30, 2024
GNFT Price
$5.92
Fair Value Price
-$5.28
Market Cap
$295.02M
52 Week Low
$2.89
52 Week High
$6.05
P/E
-9.4x
P/B
3.99x
P/S
4.52x
PEG
N/A
Dividend Yield
N/A
Revenue
$41.50M
Earnings
-$32.10M
Gross Margin
100%
Operating Margin
-59.99%
Profit Margin
-75.7%
Debt to Equity
1.56
Operating Cash Flow
-$62M
Beta
0.57
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GNFT Overview
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GNFT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GNFT ($5.92) is overvalued by 212.03% relative to our estimate of its Fair Value price of -$5.28 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GNFT ($5.92) is not significantly undervalued (212.03%) relative to our estimate of its Fair Value price of -$5.28 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GNFT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GNFT due diligence checks available for Premium users.
Be the first to know about important GNFT news, forecast changes, insider trades & much more!
GNFT News
Valuation
GNFT fair value
Fair Value of GNFT stock based on Discounted Cash Flow (DCF)
Price
$5.92
Fair Value
-$5.28
Undervalued by
212.03%
GNFT ($5.92) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GNFT ($5.92) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GNFT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GNFT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-9.4x
Industry
-36.61x
Market
29.76x
GNFT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.99x
Industry
5.99x
GNFT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GNFT's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
GNFT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
GNFT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$193.2M
Liabilities
$117.7M
Debt to equity
1.56
GNFT's short-term assets ($122.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GNFT's short-term assets ($122.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GNFT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GNFT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
GNFT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GNFT vs Biotech Stocks
Genfit Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.